Outpatient chemotherapy with S-1 for recurrent head and neck cancer

Taku Yamashita, Seiichi Shinden, Takahisa Watabe, Akihiro Shiotani

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Background: This retrospective study evaluates the efficacy and safety of S-1 chemotherapy or S-1 followed by low-dose docetaxel chemotherapy for recurrent head and neck cancer. Patients and Methods: S-1 was administered to 21 patients with recurrent head and neck cancer, in outpatient settings. Of these 21 patients, 8 were additionally administered a low dose of docetaxel fortnightly. Results: The survival rate of patients with squamous cell carcinoma of the head and neck was 59.1% for 12 months and 17.5% for 24 months, with a median survival time of 18 months. Time to progression of more than 12 months was shown by 4 patients (22.2%). Most adverse events were mild (up to grade 2). Conclusion: S-1 therapy is considered a safe and effective treatment option. From the viewpoint of tumour dormancy, S-1 therapy is a useful vigorous anticancer treatment that can be provided while maintaining patients' quality of life in recurrent cases.

Original languageEnglish
Pages (from-to)577-581
Number of pages5
JournalAnticancer research
Issue number2
Publication statusPublished - 2009 Feb
Externally publishedYes


  • Low dose chemotherapy
  • Outpatient chemotherapy
  • Recurrent head and neck cancer
  • S-1
  • Tumor dormancy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Outpatient chemotherapy with S-1 for recurrent head and neck cancer'. Together they form a unique fingerprint.

Cite this